ZEB1 regulates BCL2 in cancer-associated fibroblasts to promote cholangiocarcinoma chemoresistance to gemcitabine and cisplatin

Le résumé fourni par la source

Abstract Intrahepatic cholangiocarcinoma (iCCA) is an agressive tumour from the biliary tree that is characterized by a prominent desmoplastic stroma mainly composed of cancer-associated fibroblasts (CAF) and a poor prognosis due to its late clinical presentation and the lack of effective non-surgical treatments. Current therapies still include chemotherapeutic combinations of gemcitabine and cisplatin for the majority of the patients showing poor results due the apparition of resistance. This situation led us to interrogate the potential role in the development of chemoresistance of ZEB1, an EMT-inducing transcription factor (EMT-TF) that we previously identified as a pro tumorigenic factor in tumour cells and CAF of iCCA. By analysing human CCA samples and sc-RNAseq public databases, we show here that ZEB1 is present in the tumour microenvironment of all iCCA patients tested and is prominently expressed by CAF. Using cellular models of CAF, we show that cells depleted for ZEB1 are more sensitive to gemcitabine and cisplatin, via a mechanism involving the regulation of the anti-apoptotic gene BCL2. Moreover, ZEB1 expressing CAF protect iCCA tumour cells against the toxicity of the chemotherapeutic drugs, an event that could be reversed by a BCL2 inhibitor venetoclax. Therefore, our results point to the use of BCL2 inhibitors to improve the efficacy of current chemotherapeutic regimens of gemcitabine and cisplatin in iCCA patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.